Oncology
9 drugs are in development for Non-Small Cell Lung Cancer.
- Companies
- 9
- Clinical trials
- 117
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Non-Small Cell Lung Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(2)
| Drug | Company |
|---|---|
| ivonescimab | Summit Therapeutics Inc. (SMMT) |
| Plinabulin | BeyondSpring Inc. (BYSI) |
Phase 2(1)
Phase 1(3)
| Drug | Company |
|---|---|
| JANX008 | Janux Therapeutics, Inc. (JANX) |
| lncb74 | NextCure, Inc. (NXTC) |
| stro-006 | SUTRO BIOPHARMA, INC. (STRO) |
Phase 1/Phase 2(3)
About this indication
Non-Small Cell Lung Cancer context
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung (D002289)
Also known as: Carcinomas, Non-Small-Cell Lung, Non Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Non-Small Cell Lung Cancer?
BioSniper tracks 9 drugs in development for Non-Small Cell Lung Cancer across 9 companies.
How many clinical trials target Non-Small Cell Lung Cancer?
There are 117 clinical trials targeting Non-Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Non-Small Cell Lung Cancer?
The estimated prevalence of Non-Small Cell Lung Cancer is approximately 75.0 per 100,000 population.